To ask Her Majesty’s Government why the protection afforded to small and medium-sized enterprises with sales between £5 million and £25 million under the previous Pharmaceutical Price Regulation Scheme has not been carried forward into the new scheme.
To ask Her Majesty’s Government what assessment they have made of the impact of the new Pharmaceutical Price Regulation Scheme on future research and development investment by small and medium-sized biopharmaceutical enterprises.
The 2014 Pharmaceutical Price Regulation Scheme (PPRS) was agreed with the Association of the British Pharmaceutical Industry. It did not include the exemption from certain requirements for companies with health service sales of between £5 million and £25 million a year that were a feature of the 2009 PPRS. However companies with sales of health service medicines of less than £5 million a year (not counting global sales) are exempt from making any payments under the 2014 PPRS scheme.
The PPRS benefits businesses making new medicines. A company that develops and brings a new medicine (new active substance) to the market from
The Government remains committed to ensuring that the United Kingdom is a world leading place for life science research and investment through the Strategy for UK Life Sciences. The Department has assessed the impact of the PPRS and does not believe that there will be any significant impact on research and development investment in the UK.